@Article{Chen2014,
journal="Contemporary Oncology/Współczesna Onkologia",
issn="1428-2526",
volume="18",
number="2",
year="2014",
title="Comparison of HER2 status by fluorescence in situ hybridisation and immunohistochemistry in gastric cancer",
abstract=" Aim of the study:  To investigate the differences and relevance, and to evaluate the clinical significance of fluorescence    in situ    hybridisation and immunohistochemistry (IHC) in detecting HER2 in gastric cancer tissues.   Material and methods:  The expression of HER2 protein and the amplification of the HER2 gene in 118 gastric cancer tissues were detected by immunohistochemistry and fluorescence    in situ    hybridisation, respectively.   Results : Using IHC, we found that in 40 cases (33.9%) the HER2 expression was at level 0, in 33 cases (28.0%) the HER2 expression was at level 1+, in 16 cases (14%) the HER2 expression was at level 2+, and in 29 cases (25.6%) the HER2 expression was at level 3+, respectively. Using the FISH test, 38 of 118 cases (32.2%) were judged as positive results. The concordance rate between the results of IHC and FISH in all cases was 85.6%. The concordance rate of IHC and FISH was high in cases of HER2 expression at level 0, 1+ and 3+ according to IHC, but low in cases of 2+ according to IHC (43.8%).   Conclusions:  Immunohistochemistry cannot predict HER2 gene amplification accurately. The FISH test should be executed in IHC 2+ cases.",
author="Chen, Ming
and Li, Yan
and Ming, Zhou
and Biao, Ai",
pages="95--99",
doi="10.5114/wo.2014.41383",
url="http://dx.doi.org/10.5114/wo.2014.41383"
}